223 related articles for article (PubMed ID: 25811963)
1. Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Roviello F; Marrelli D; Francini E
Anticancer Drugs; 2015 Jul; 26(6):682-6. PubMed ID: 25811963
[TBL] [Abstract][Full Text] [Related]
2. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Santini D; Virzi V; Vasile E; Vincenzi B; Catalano V; Graziano F; Masi G; Bronte G; Russo A; Falcone A; Tonini G
Oncology; 2012; 82(2):75-82. PubMed ID: 22327844
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
Graham JS; Boyd K; Coxon FY; Wall LR; Eatock MM; Maughan TS; Highley M; Soulis E; Harden S; Bützberger-Zimmerli P; Evans TR
BMC Res Notes; 2016 Mar; 9():161. PubMed ID: 26969121
[TBL] [Abstract][Full Text] [Related]
10. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Riechelmann RP; Townsley CA; Chin SN; Pond GR; Knox JJ
Cancer; 2007 Sep; 110(6):1307-12. PubMed ID: 17628484
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Iyer RV; Gibbs J; Kuvshinoff B; Fakih M; Kepner J; Soehnlein N; Lawrence D; Javle MM
Ann Surg Oncol; 2007 Nov; 14(11):3202-9. PubMed ID: 17705089
[TBL] [Abstract][Full Text] [Related]
13. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Knox JJ; Hedley D; Oza A; Feld R; Siu LL; Chen E; Nematollahi M; Pond GR; Zhang J; Moore MJ
J Clin Oncol; 2005 Apr; 23(10):2332-8. PubMed ID: 15800324
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK
Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814
[TBL] [Abstract][Full Text] [Related]
15. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Iqbal S; Rankin C; Lenz HJ; Gold PJ; Ahmad SA; El-Khoueiry AB; Messino MJ; Holcombe RF; Blanke CD
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1595-602. PubMed ID: 21556747
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Koeberle D; Saletti P; Borner M; Gerber D; Dietrich D; Caspar CB; Mingrone W; Beretta K; Strasser F; Ruhstaller T; Mora O; Herrmann R;
J Clin Oncol; 2008 Aug; 26(22):3702-8. PubMed ID: 18669455
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
Manzione L; Romano R; Germano D
Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Lee JK; Capanu M; O'Reilly EM; Ma J; Chou JF; Shia J; Katz SS; Gansukh B; Reidy-Lagunes D; Segal NH; Yu KH; Chung KY; Saltz LB; Abou-Alfa GK
Br J Cancer; 2013 Aug; 109(4):915-9. PubMed ID: 23900219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
